Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, November 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that that it submitted an application for marketing approval in...
TOKYO – November 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced new data in acute myeloid leukemia (AML) research, including...
Tokyo, November 28, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that they have...
Tokyo and San Francisco, October 31, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff,...
Tokyo, October 30, 2017 – Nippon Boehringer Ingelheim Co., Ltd. (President and Representative Director: Yoshiaki Aono, “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (President and...
Tokyo, October 30, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a screening collaboration agreement with Medicines...
Tokyo, October 19, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today...
Tokyo, October 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a new collaborative research agreement with TB...
Tokyo and Osaka, October 11, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; Headquarters: Tokyo; TSE: 4503; “Astellas” ), Mitsubishi Tanabe Pharma Corporation (President...
TOKYO and BOTHELL, Wash., October 10, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Seattle Genetics Inc., Inc., (NASDAQ: SGEN) today announced...
TOKYO – October 11, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has granted...
Astellas Pharm Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and TOA EIYO LTD. (President: Atsuo Takahashi, “TOA EIYO”) announced that the companies have entered into...
Pfizer Contacts: For Media Sally Beatty (212) 733-6566 sally.beatty@pfizer.com For Investors Chuck Triano (212) 733-3901 charles.e.triano@pfizer.com Astellas Contact: For Media Tyler Marciniak...
Tokyo, Sept. 12, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for...
Tokyo, September 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has submitted a supplemental new drug application for...
TOKYO (August 30, 2017) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters,...
TOKYO – August 22, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the first patient was dosed in the registrational Phase 3...
(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) Tokyo, August 1, 2017- Astellas Pharma Inc. (TSE: 4503, President and CEO:...
Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Pharma Inc....
Tokyo, July 31, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has submitted an application for marketing approval of...
Follow us
